Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 36 14 69
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 51

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
ICD10 32 C45.0
NCIt 46 C7376
KEGG 36 H00015
UMLS 69 C0812413

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to adenocarcinoma and sarcomatoid mesothelioma, and has symptoms including malaise, chills and fatigue. An important gene associated with Malignant Pleural Mesothelioma is SPP1 (Secreted Phosphoprotein 1), and among its related pathways/superpathways are Pathways in cancer and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Alimta and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotypes are cardiovascular system and cellular

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.4 BIRC5 CDKN2A EGFR MET MUC1
2 sarcomatoid mesothelioma 29.6 CDKN2A MUC1 NKX2-1 THBD WT1
3 lung cancer 29.1 BIRC5 CDH2 CDKN2A EGFR MET NKX2-1
4 renal cell carcinoma, nonpapillary 29.0 CDH2 EGFR MET MSLN MUC1 NKX2-1
5 mesothelioma, malignant 27.9 BAP1 CALB2 CDH2 CDKN2A CEACAM3 LINC01194
6 pancreatic cancer 27.6 BIRC5 CDH2 CDKN2A CEACAM3 EGFR MET
7 fallopian tube squamous cell carcinoma 10.5 CDKN2A WT1
8 fallopian tube carcinosarcoma 10.5 CALB2 WT1
9 fallopian tube endometrioid adenocarcinoma 10.5 CALB2 CDKN2A
10 ovarian serous cystadenofibroma 10.5 CALB2 MUC1
11 breast scirrhous carcinoma 10.5 EGFR MUC1
12 anaplastic oligodendroglioma 10.5 CDKN2A EGFR
13 squamous cell carcinoma of the larynx 10.5 CDKN2A EGFR
14 orbital lymphangioma 10.5 EGFR PDPN
15 horseshoe kidney 10.4 CALB2 EGFR NKX2-1
16 gastric adenosquamous carcinoma 10.4 CDKN2A EGFR
17 endosalpingiosis 10.4 MUC1 WT1
18 sertoli cell tumor 10.4 CALB2 MUC1 WT1
19 malignant ovarian surface epithelial-stromal neoplasm 10.4 MSLN MUC1 WT1
20 ovary epithelial cancer 10.4 MSLN MUC1 WT1
21 melanomatosis 10.4 CDKN2A WT1
22 hobnail hemangioma 10.4 PDPN WT1
23 rhabdoid cancer 10.4 MUC1 SPP1 WT1
24 salivary gland cancer 10.4 BIRC5 EGFR MET
25 renal clear cell carcinoma 10.3 BIRC5 MSLN MUC1
26 keratocystic odontogenic tumor 10.3 BIRC5 CALB2 PDPN
27 osteofibrous dysplasia 10.3 MET MUC1 SPP1
28 pericardium cancer 10.3 CALB2 MSLN THBD
29 pre-malignant neoplasm 10.3 CDKN2A EGFR PDPN
30 malignant peripheral nerve sheath tumor 10.3 CDKN2A EGFR MUC1
31 lymphohistiocytoid mesothelioma 10.3 CALB2 CDKN2A THBD
32 pancreas adenocarcinoma 10.3 CDKN2A EGFR MSLN MUC1
33 female reproductive organ cancer 10.3 CDKN2A EGFR MSLN MUC1
34 malignant peritoneal mesothelioma 10.3 BIRC5 CDKN2A EGFR MUC1
35 pancreatic ductal adenocarcinoma 10.3 CDKN2A EGFR MSLN MUC1
36 pneumatosis cystoides intestinalis 10.3 CALB2 PDPN WT1
37 gallbladder cancer 10.3 CDKN2A EGFR MUC1
38 rete testis adenocarcinoma 10.3 CALB2 NKX2-1 THBD
39 ovarian cancer 1 10.3 EGFR MSLN MUC1 WT1
40 rete testis neoplasm 10.3 CALB2 NKX2-1 THBD
41 adenomatoid tumor 10.3 CALB2 THBD WT1
42 thymus cancer 10.3 CALB2 EGFR MUC1 NKX2-1
43 endometrial squamous cell carcinoma 10.3 CDKN2A MET
44 sarcoma, synovial 10.3 CALB2 MET MUC1
45 malignant epithelial mesothelioma 10.3 CALB2 THBD WT1
46 mucinous adenocarcinoma 10.3 CDKN2A EGFR MUC1 NKX2-1
47 ovarian brenner tumor 10.3 CALB2 THBD WT1
48 mucinous bronchioloalveolar adenocarcinoma 10.3 CALB2 CDKN2A MUC1 NKX2-1
49 blood group, i system 10.2
50 interstitial lung disease 10.2 EGFR MUC1 NKX2-1

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


malaise, chills, fatigue, dyspnea, chest pain

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 BAP1 CDH2 CDKN2A EFEMP1 EGFR MET
2 cellular MP:0005384 10.34 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
3 growth/size/body region MP:0005378 10.32 BAP1 CDH2 CDKN2A EFEMP1 EGFR MET
4 homeostasis/metabolism MP:0005376 10.29 BAP1 BIRC5 CDH2 CDKN2A EFEMP1 EGFR
5 hematopoietic system MP:0005397 10.24 EGFR PDPN PPP1R15A SPP1 THBD WT1
6 immune system MP:0005387 10.23 BAP1 BIRC5 CDKN2A EFEMP1 EGFR MET
7 mortality/aging MP:0010768 10.21 BAP1 XIAP BIRC5 CDH2 CDKN2A EFEMP1
8 endocrine/exocrine gland MP:0005379 10.18 BAP1 BIRC5 CDKN2A EFEMP1 EGFR MET
9 digestive/alimentary MP:0005381 10.15 EGFR MET NKX2-1 PDPN THBD BAP1
10 embryo MP:0005380 10.14 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
11 integument MP:0010771 10.03 BAP1 CDKN2A EFEMP1 EGFR PDPN SPP1
12 muscle MP:0005369 10.02 BAP1 CDH2 CDKN2A EFEMP1 EGFR MET
13 liver/biliary system MP:0005370 9.95 MET SPP1 THBD WT1 CDKN2A EFEMP1
14 normal MP:0002873 9.9 CALB2 EFEMP1 EGFR MET MSLN NKX2-1
15 neoplasm MP:0002006 9.8 BAP1 CDKN2A EGFR MET NKX2-1 SPP1
16 reproductive system MP:0005389 9.61 BAP1 CDKN2A EFEMP1 EGFR NKX2-1 SPP1
17 respiratory system MP:0005388 9.28 THBD WT1 BAP1 CDKN2A EGFR MET

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Alimta 17 45 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
6
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 5460373 44475014 11953898
7
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
8
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
10
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
11
Raltitrexed Approved, Investigational Phase 3,Phase 1,Phase 2 112887-68-0 104758
12
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
13
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
14
nivolumab Approved Phase 3,Phase 2 946414-94-4
15
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
16
Nintedanib Approved Phase 3,Phase 2 656247-17-5 56843413
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
18
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3 13422-55-4
19
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21
Doxil Approved June 1999 Phase 3,Phase 2 31703
22 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
23 Micronutrients Phase 3,Phase 2
24 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
26 Trace Elements Phase 3,Phase 2
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
28 Vitamin B 12 Phase 2, Phase 3
29 Vitamin B Complex Phase 3,Phase 2,Phase 1
30 Vitamins Phase 2, Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
32 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Antiemetics Phase 3,Phase 2,Phase 1
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 3,Phase 2,Phase 1
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2,Phase 1
39 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 3,Phase 2,Phase 1
41 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
42 Antibodies Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 BB 1101 Phase 3,Phase 2,Phase 1
45 Autonomic Agents Phase 3,Phase 2,Phase 1
46 Antiviral Agents Phase 3,Phase 2,Phase 1
47 Analgesics Phase 3,Phase 2,Phase 1
48 Alkylating Agents Phase 3,Phase 2,Phase 1
49 Mitomycins Phase 3
50 Histone Deacetylase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 184)

# Name Status NCT ID Phase Drugs
1 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
3 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
5 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
6 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
7 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
9 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
10 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
11 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
12 Nintedanib (BIBF 1120) in Mesothelioma Active, not recruiting NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
13 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Terminated NCT01604005 Phase 3
14 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
15 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
16 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
17 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
18 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
19 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
20 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
21 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
22 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
23 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
24 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00484276 Phase 2 NGR-hTNF
25 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
26 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
27 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
28 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
29 Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. Completed NCT02004028 Phase 2 VS-6063
30 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
31 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed NCT01112293 Phase 2 GC1008
32 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
33 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
34 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
35 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00513877 Phase 2 bortezomib
36 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
37 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
38 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium
39 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
40 Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Completed NCT00407459 Phase 2 Bevacizumab, Pemetrexed, Carboplatin
41 Nivolumab in Patients With Recurrent Malignant Mesothelioma Completed NCT02497508 Phase 2 nivolumab
42 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00770120 Phase 2 everolimus
43 A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. Completed NCT00996567 Phase 2 Cetuximab (Erbitux)
44 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2 liposomal NDDP
45 Isolated Thoracic Perfusion (ITP-F) for MPM Completed NCT02467426 Phase 2 Chemotherapy
46 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00101283 Phase 2 pemetrexed disodium;gemcitabine hydrochloride;carboplatin
47 Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Completed NCT00165516 Phase 2 Cisplatin;Sodium Thiosulfate
48 Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Completed NCT00087698 Phase 2 pemetrexed;cisplatin
49 Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma Completed NCT01211275 Phase 1, Phase 2 chemotherapy
50 S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery Completed NCT00003723 Phase 2 gemcitabine hydrochloride

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

38
Lung, T Cells, Endothelial, Testes, Liver, Thymus, Lymph Node

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 834)
# Title Authors Year
1
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. ( 29346042 )
2018
2
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. ( 29338319 )
2018
3
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. ( 29399399 )
2018
4
Radical multimodality therapy for malignant pleural mesothelioma. ( 29309720 )
2018
5
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. ( 29387394 )
2018
6
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. ( 29438360 )
2018
7
Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. ( 29303405 )
2018
8
Correction: Apoptosis by [Pt(O,O'-acac)(I^-acac)(DMS)] requires PKC-I' mediated p53 activation in malignant pleural mesothelioma. ( 29432478 )
2018
9
Variation in incidence trends of malignant pleural mesothelioma in Europe. ( 29437947 )
2018
10
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. ( 29362358 )
2018
11
Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania. ( 29400553 )
2018
12
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. ( 29413055 )
2018
13
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. ( 29313814 )
2018
14
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. ( 29444986 )
2018
15
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience. ( 29367501 )
2018
16
Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma. ( 29356044 )
2018
17
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. ( 28892431 )
2017
18
Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. ( 28027744 )
2017
19
Radiotherapy for the treatment of malignant pleural mesothelioma. ( 28884702 )
2017
20
Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. ( 28919393 )
2017
21
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : AA propensity score matching of the SEER database. ( 28044200 )
2017
22
The value of delayed phase enhanced imaging in malignant pleural mesothelioma. ( 28932538 )
2017
23
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. ( 27979596 )
2017
24
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib. ( 28838714 )
2017
25
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. ( 28948332 )
2017
26
Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM). ( 28066892 )
2017
27
Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy. ( 28856921 )
2017
28
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. ( 28870611 )
2017
29
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). ( 28862644 )
2017
30
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. ( 28843362 )
2017
31
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response ( 28843224 )
2017
32
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. ( 29371938 )
2017
33
<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. ( 29386699 )
2017
34
Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis. ( 28103581 )
2017
35
Open access phone triage for veterans with suspected malignant pleural mesothelioma. ( 27979465 )
2017
36
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis. ( 28915685 )
2017
37
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. ( 29100432 )
2017
38
Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. ( 28182302 )
2017
39
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study. ( 28757678 )
2017
40
Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. ( 28838403 )
2017
41
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. ( 28051015 )
2017
42
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. ( 27881012 )
2017
43
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. ( 28197626 )
2017
44
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma. ( 28918032 )
2017
45
Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report. ( 29312767 )
2017
46
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. ( 28027772 )
2017
47
Clinical staging of malignant pleural mesothelioma: current perspectives. ( 28860886 )
2017
48
Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells. ( 28476806 )
2017
49
New Keywords in the Treatment of Malignant Pleural Mesothelioma. ( 28935312 )
2017
50
Prognostic and predictive role of [(18) F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. ( 28941158 )
2017

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.28 BIRC5 CDKN2A EGFR MET XIAP
2 11.42 BAP1 CDH2 SPP1
3 11 BIRC5 CDKN2A XIAP
4 10.62 CDH2 EFEMP1 EGFR MET SPP1
5 10.47 CDH2 MET SPP1

GO Terms for Malignant Pleural Mesothelioma

Cellular components related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.26 CDH2 EGFR MUC1 PDPN
2 cell surface GO:0009986 9.02 CDH2 EGFR MET MSLN THBD

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.55 BIRC5 EGFR PDPN WT1 XIAP
2 lung development GO:0030324 9.43 EGFR NKX2-1 PDPN
3 positive regulation of bone resorption GO:0045780 9.32 EGFR SPP1
4 cerebral cortex cell migration GO:0021795 8.96 EGFR NKX2-1
5 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 8.62 BIRC5 XIAP

Molecular functions related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 CDH2 EGFR MET
2 epidermal growth factor-activated receptor activity GO:0005006 8.62 EFEMP1 EGFR

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....